Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

Abstract Background Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) for which several new treatment options were recently introduced. Among them is the monoclonal anti-CD52 antibody alemtuzumab that depletes mainly B cells and T cells in the immune periphe...

Full description

Bibliographic Details
Main Authors: Micha Simon, Rojda Ipek, György A. Homola, Damiano M. Rovituso, Andrea Schampel, Christoph Kleinschnitz, Stefanie Kuerten
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Journal of Neuroinflammation
Subjects:
Alemtuzumab
B cells
CD52
CNS
EAE
MS
Online Access:http://link.springer.com/article/10.1186/s12974-018-1263-9

Internet

http://link.springer.com/article/10.1186/s12974-018-1263-9

Similar Items